Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
FTAAU FTAC Athena Acquisition Corp
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
LGO Largo Inc
ONTO Onto Innovation Inc
OFED Oconee Federal Financial Corp
WKEY Wisekey International Holding AG
FPH Five Point Holdings LLC
FATE Fate Therapeutics Inc
MCD McDonald's Corp

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Closing Price
Day's Change
-1.12 (-0.76%)
B/A Size
Day's High
Day's Low

10-day average volume:

Apple will delay AR glasses, focus instead on cheaper mixed-reality headset: report

7:54 am ET January 18, 2023 (MarketWatch)

By Mike Murphy

Apple's first MR headset still expected to be released this year

Apple Inc. is expected to release its first mixed-reality headset later this year, but the release of its highly anticipated follow-up product, augmented-reality glasses, has been postponed, according to a new report.

Bloomberg News reported Tuesday night that the lightweight AR glasses faced technical challenges, and will be delayed indefinitely and work on it pared back. Instead, Apple plans to release a lower-cost mixed-reality headset in 2024 or 2025, Bloomberg reported, citing sources familiar with Apple's plans.

The mixed-reality headset still on track for 2023 is expected to cost about $3,000, with the next version potentially priced around $1,500, Bloomberg reported. According to the report, Apple's MR headset is less complicated to build -- though bulkier -- than an AR device that resembles normal eyeglasses.

While virtual reality is completely immersive, augmented reality overlays virtual information, such as images, text and animation, over the real world. Mixed reality mixes real-world and digital elements, allowing users to interact in a virtual environment.

Earlier Tuesday, Apple announced upgrades to its MacBook Pro line of laptops and a new version of the Mac mini.

Apple shares (AAPL) are down about 21% over the past 12 months, compared to a decline of about 6% for the Dow Jones Industrial Average , of which it is a component.

-Mike Murphy


(END) Dow Jones Newswires

January 18, 2023 07:54 ET (12:54 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.